Gilead Sciences and NIH Initiate Two Phase 3 Studies of Investigational Antiviral Remdesivir for the Treatment of COVID-19
In February, Gilead Sciences and the National Institutes of Health, both partners of the Coalition, announced the initiation of two Phase 3 clinical studies to evaluate the safety and efficacy of remdesivir in adults diagnosed with COVID-19 (novel coronavirus). These randomized, open-label, multicenter studies will enroll approximately 1,000 patients at medical centers globally with high numbers of diagnosed cases, beginning in March. The studies will assess two dosing durations of remdesivir, administered intravenously.
View the full press release from Gilead Sciences here:
View the news release from the National Institutes of Health here:
View the studies on Clinical Trials.gov:
Early results on the remdesivir study can be found here: